Calculation
ROA | = | 100 | × | Net earnings attributable to AbbVie Inc.1 | ÷ | Total assets1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2023 | 3.61% | = | 100 | × | 4,863) | ÷ | 134,711) |
Dec 31, 2022 | 8.53% | = | 100 | × | 11,836) | ÷ | 138,805) |
Dec 31, 2021 | 7.88% | = | 100 | × | 11,542) | ÷ | 146,529) |
Dec 31, 2020 | 3.07% | = | 100 | × | 4,616) | ÷ | 150,565) |
Dec 31, 2019 | 8.84% | = | 100 | × | 7,882) | ÷ | 89,115) |
Dec 31, 2018 | 9.58% | = | 100 | × | 5,687) | ÷ | 59,352) |
Dec 31, 2017 | 7.50% | = | 100 | × | 5,309) | ÷ | 70,786) |
Dec 31, 2016 | 9.01% | = | 100 | × | 5,953) | ÷ | 66,099) |
Dec 31, 2015 | 9.70% | = | 100 | × | 5,144) | ÷ | 53,050) |
Dec 31, 2014 | 6.44% | = | 100 | × | 1,774) | ÷ | 27,547) |
Dec 31, 2013 | 14.14% | = | 100 | × | 4,128) | ÷ | 29,198) |
Dec 31, 2012 | 19.53% | = | 100 | × | 5,275) | ÷ | 27,008) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$ in millions
Comparison to Competitors
AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2023 | 3.61% | 6.91% | 8.43% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 6.07% |
Dec 31, 2022 | 8.53% | 10.06% | 6.53% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 7.15% |
Dec 31, 2021 | 7.88% | 9.63% | 6.40% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 8.12% |
Dec 31, 2020 | 3.07% | 11.54% | -7.61% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 9.23% |
Dec 31, 2019 | 8.84% | 13.13% | 2.65% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 6.33% |
Dec 31, 2018 | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% |
Dec 31, 2017 | 7.50% | 2.48% | 3.00% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 3.93% |
Dec 31, 2016 | 9.01% | 9.95% | 13.22% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | 4.40% |
Dec 31, 2015 | 9.70% | 9.69% | 4.93% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | 4.83% |
Dec 31, 2014 | 6.44% | 7.47% | 5.94% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | 4.42% |
Dec 31, 2013 | 14.14% | 7.68% | 6.64% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | 4.00% |
Dec 31, 2012 | 19.53% | 8.00% | 5.46% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | 4.29% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2023 | 3.61% | 7.08% |
Dec 31, 2022 | 8.53% | 10.55% |
Dec 31, 2021 | 7.88% | 10.33% |
Dec 31, 2020 | 3.07% | 5.25% |
Dec 31, 2019 | 8.84% | 8.97% |
Dec 31, 2018 | 9.58% | 8.78% |
Dec 31, 2017 | 7.50% | 5.27% |
Dec 31, 2016 | 9.01% | 8.66% |
Dec 31, 2015 | 9.70% | 9.03% |
Dec 31, 2014 | 6.44% | 9.59% |
Dec 31, 2013 | 14.14% | 9.55% |
Dec 31, 2012 | 19.53% | 8.35% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
AbbVie Inc. | Health Care | |
---|---|---|
Dec 31, 2023 | 3.61% | 6.35% |
Dec 31, 2022 | 8.53% | 8.30% |
Dec 31, 2021 | 7.88% | 8.19% |
Dec 31, 2020 | 3.07% | 5.42% |
Dec 31, 2019 | 8.84% | 7.18% |
Dec 31, 2018 | 9.58% | 6.12% |
Dec 31, 2017 | 7.50% | 5.31% |
Dec 31, 2016 | 9.01% | 6.93% |
Dec 31, 2015 | 9.70% | 7.37% |
Dec 31, 2014 | 6.44% | 8.18% |
Dec 31, 2013 | 14.14% | 8.29% |
Dec 31, 2012 | 19.53% | 7.68% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).